UPDATE ON PFIZER’S PHASE 1B OPEN-LABEL MINI-DYSTROPHIN GENE THERAPY TRIAL FOR DUCHENNE, page-12

Itsa,

And for those who might not open your referenced item:-

"CAP-1002 (Capricor), ATL1102 (Antisense)CAP-1002 is a cell therapy targeting improvement in the upper limb function, cardiac function, pulmonary function, and other endpoints. It is expected to compete to some extent with ATL1102 as Antisense is also targeting improvement in upper limb function. It is estimated that ATL1102 has significant potential to capture the non-ambulatory patient pool, given the low level of competition. Additionally, ATL1102 reported highly promising Phase II trial results. The current standard of care for non-ambulatory patients is long-term corticosteroid use which is associated with significant side effects. Thus, it is believed that the drug has a great growth opportunity to capture a large patient share of the non-ambulant DMD market. Furthermore, it is anticipated that the drug will launch in EU5 prior to its launch in the US, given the feedback on the Paediatric Investigation Plan (PIP) for the development of the drug from the Paediatric Committee (PDCO) of the EMA. The drug is also expected to reduce the usage of corticosteroids."